AstraZeneca plc’s (AZN) “Hold” Rating Reaffirmed at Jefferies Group LLC
Jefferies Group LLC reiterated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Thursday morning. They currently have a GBX 5,100 ($67.08) price objective on the biopharmaceutical company’s stock.
Other analysts also recently issued research reports about the stock. Credit Suisse Group lowered their target price on shares of AstraZeneca plc from GBX 5,000 ($65.76) to GBX 4,700 ($61.82) and set a neutral rating on the stock in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.30) target price on shares of AstraZeneca plc and gave the company a sell rating in a report on Wednesday, August 2nd. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a report on Wednesday, August 2nd. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a research note on Friday, November 10th. Finally, Investec raised their price objective on shares of AstraZeneca plc from GBX 4,900 ($64.45) to GBX 5,500 ($72.34) and gave the company a buy rating in a research note on Monday, November 6th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 5,150.82 ($67.75).
Shares of AstraZeneca plc (LON AZN) traded down GBX 35.90 ($0.47) during trading hours on Thursday, hitting GBX 4,975.10 ($65.44). 1,500,000 shares of the stock traded hands, compared to its average volume of 2,120,000. AstraZeneca plc has a 1-year low of GBX 3,996 ($52.56) and a 1-year high of GBX 5,520 ($72.60).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.